Wang Yuzhi, Lu Jiandong, Dai Wenkui, Yang Shudong
The Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China.
Department of Nephrology, Shenzhen Traditional Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, China.
Front Cell Infect Microbiol. 2025 Jul 9;15:1526863. doi: 10.3389/fcimb.2025.1526863. eCollection 2025.
Recent studies have underscored the role of interactions between Traditional Chinese Medicine (TCM) and the gut microbiome (GM) in mediating therapeutic effects. Jian-Pi-Yi-Shen Formula (JPYSF) has shown efficacy in ameliorating chronic kidney disease (CKD) symptoms, but its mechanisms via GM modulation remain unclear.
In this study, 8-week-old rats were assigned to three groups after a two-week acclimation: C (normal diet for six weeks), M (adenine diet for four weeks then normal diet for two weeks), and T (same as M, with JPYSF administered during the final three weeks). Fecal samples were collected at three timepoints (T1: post-acclimation; T2: after three weeks on respective diets; T3: after three weeks of JPYSF treatment) for metagenomic sequencing. Serum creatinine (SCR) was measured at T2 and T3.
At T2, adenine-fed rats showed elevated SCR (C: 28.4 ± 1.5 µmol/L; M: 189.6 ± 25.8µmol/L; T: 186.4 ± 32.5µmol/L; p < 0.001). By T3, SCR decreased more in T (86.0 ± 14.9µmol/L) than in M (119.6 ± 16.3µmol/L; p = 0.012), with C remaining stable (30.8 ± 4.4µmol/L). Adenine feeding induced significant GM shifts, evidenced by increased Aitchison distance (p < 0.01) and altered co-abundance interaction groups (CIGs): CIG3, 6, 9, 10 increased; CIG1, 2, 4, 12 decreased (all p < 0.05). After JPYSF treatment, only CIG4 significantly rebounded (T3 vs. M, p = 0.0079), and T3-T1 dissimilarity was lower in T than M (p < 0.05). SCR levels were significantly lower in T than M after returning to a normal diet, suggesting a renoprotective effect of JPYSF. Co-occurrence analysis linked SCR positively with toxin-associated CIGs (CIG3, 6, 7, 9, 10) and pathways (purine metabolism, toluene degradation), and negatively with CIG4.
These results demonstrate that JPYSF lowers SCR and selectively modulates GM modules, particularly CIG4, which inversely correlates with uremic toxin-producing pathways, suggesting improved renal function and specific gut microbiota modulation in CKD rats.
近期研究强调了中药(TCM)与肠道微生物群(GM)之间的相互作用在介导治疗效果中的作用。健脾益肾方(JPYSF)已显示出改善慢性肾脏病(CKD)症状的功效,但其通过调节肠道微生物群的机制仍不清楚。
在本研究中,8周龄大鼠在适应两周后被分为三组:C组(六周正常饮食)、M组(四周腺嘌呤饮食,然后两周正常饮食)和T组(与M组相同,但在最后三周给予JPYSF)。在三个时间点(T1:适应后;T2:各自饮食三周后;T3:JPYSF治疗三周后)收集粪便样本进行宏基因组测序。在T2和T3测量血清肌酐(SCR)。
在T2时,喂食腺嘌呤的大鼠SCR升高(C组:28.4±1.5µmol/L;M组:189.6±25.8µmol/L;T组:186.4±32.5µmol/L;p<0.001)。到T3时,T组(86.0±14.9µmol/L)的SCR下降幅度大于M组(119.6±16.3µmol/L;p=0.012),C组保持稳定(30.8±4.4µmol/L)。腺嘌呤喂养导致肠道微生物群显著变化,艾奇逊距离增加(p<0.01)和共丰度相互作用组(CIGs)改变证明了这一点:CIG3、6、9、10增加;CIG1、2、4、12减少(均p<0.05)。JPYSF治疗后,只有CIG4显著反弹(T3与M组相比,p=0.0079),且T组T3与T1的差异低于M组(p<0.05)。恢复正常饮食后,T组的SCR水平显著低于M组,表明JPYSF具有肾脏保护作用。共现分析将SCR与毒素相关CIGs(CIG3、6、7、9、10)和途径(嘌呤代谢、甲苯降解)呈正相关,与CIG4呈负相关。
这些结果表明,JPYSF降低了SCR并选择性地调节肠道微生物群模块,特别是CIG4,其与尿毒症毒素产生途径呈负相关,提示CKD大鼠的肾功能得到改善且肠道微生物群得到特异性调节。